Vaccination with PANHPVAX 10µg

Phase 1Biologic

GGerman Cancer Research Center

Vaccination with PANHPVAX 10µg is one of 4 biologic programs targeting HPV Vaccine. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

HPV VaccineRecruiting

HPV VaccinePhase 1

Recruiting

Competition

Competitive Landscape

4 competitors in HPV Vaccine

#DrugCompanyPhaseTrials

HPV Vaccine

SShanghai Zerun Biotechnology Co.,Ltd

Phase 3

1 2

Nonavalent HPV Vaccine

XXiamen University

Phase 3

1 3

Bivalent HPV Vaccine

ZZagazig University

Phase 2

1 4

Vaccination with PANHPVAX 10µg

GGerman Cancer Research Center

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

Phase 1Recruiting

HPV Vaccine

NCT05208710

Clinical

Trials by Indication[1]

HPV Vaccine1 trial

PANHPVAX, Study of a New HPV Vaccine in Healthy Volunteers

Recruiting·GGerman Cancer Research Center·Phase 1·NCT05208710·45 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Vaccination with PANHPVAX 10µg. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Vaccination with PANHPVAX 10µg compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Vaccination with PANHPVAX 10µg. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — German Cancer Research Center company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 1[1]
Company: GGerman Cancer Research Center

Vaccination with PANHPVAX 10µg

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Trials by Indication[1]

HPV Vaccine1 trial

References

Drug Info

Quick Facts

Related News